Navigation Links
Stem Cell Therapy to Skyrocket by 2017
Date:9/13/2007

Although still in its infancy, stem cell therapy market to grow rapidly

over next decade

WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group (MRG) has conducted a detailed analysis of the stem cell therapy market in its US Markets for Stem Cell Therapies 2007 report. The analysis reveals that although the market for stem cell therapies is in its infancy, it will grow rapidly as products are approved in the US. Today, only two products are on the market, but by 2017, almost 90 are expected to be available.

Stem cells have regenerative capabilities, and promise lasting treatments for chronic disorders and potential cures for currently 'incurable' diseases. In 2007, the US stem cell therapies market earned over $25 million in revenues, with only two orthopedic products available in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity. Aside from these two products, the development of the US market for stem cell therapies is largely dependent on the success of clinical trials, regulatory approval, and public acceptance. The first products in the cardiovascular, diabetes, neurological, and tissue and organ stem cell therapy markets are expected to enter the market between 2009 and 2013. The entry of these products will open up a new realm of treatable disorders, offering hope to patients and vast market potential.

"This market has almost everything going its way", says Chris Schutz, senior analyst at MRG. "The big question mark however is the political and public support. The prevalence of potentially treatable disorders, unmet medical needs, rising health care costs, growth in the aging population, and the success of the first stem cell therapy products are all factors that will drive this market upward through 2017."

The US Markets for Stem Cell Therapies 2007 report includes coverage of companies offering or developing products for the stem cell therapy market, including Aas
'/>"/>

SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. TomoTherapy opens technical training center
4. TomoTherapy raises $223 million in IPO
5. TomoTherapy revises IPO money target
6. Stem cell therapy shows visionary promise
7. Hospital named for Madame Curie installs TomoTherapy system
8. TomoTherapy files registration statement for IPO
9. TomoTherapy to sell medical devices in India
10. TomoTherapy sees sustained market advantage
11. Mirus granted European patent for gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... As part of its philanthropic partnership with Banner ... funded a $3.25 million project to relocate and equip ... up-to-date features and technology. , The new pharmacy is ... members will begin moving from the current location to ... , The current pharmacy has been using a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ... Technologies in HW_Technical Insights" report to their offering. ... technology trends in the Health and Wellness sector and ... have an impact in the year 2015. The research ... 10 health and wellness technologies that are anticipated to ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2
... VIEW, Calif., Jan. 26 Based on its ... & Sullivan recognizes ESBATech with the 2009 North ... Year Award for its work in developing antibody ... antibody fragment therapeutics addresses and overcomes many of ...
... (OTC Bulletin Board: PDAE) today announced that its Hereford ... under Chapter 11 of the United States Bankruptcy Code ... District of Texas. The company intends to sell its ... Section 363 sale process approved by the bankruptcy court. ...
... JOLLA, Calif., Jan. 23 Cordex Pharma, Inc., formerly known ... that it will host a scientific briefing on Thursday, January ... The keynote speaker will be Jonathan S. Stamler, MD, the ... a Professor of Medicine and of Biochemistry at Duke ...
Cached Biology Technology:Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 2Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 3Frost & Sullivan Recognizes ESBATech's Innovation in Developing Antibody Fragments for Biologic Therapeutics 4Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 2Panda Ethanol's Hereford, Texas Subsidiary Files Voluntary Chapter 11 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... PITTSBURGHCarnegie Mellon University researchers have found that within ... neurons that behave much like people in social networks. ... of highly active members who give and receive more ... Barth, associate professor of biological sciences at Carnegie Mellon ...
... 10, 2011 Cleveland Researchers have discovered a ... undergo testing for genetic mutations of the tumor suppressor ... including several types of cancers. The research has created ... Led by Charis Eng, M.D., Ph.D., Chair of ...
... (January 9, 2011) - While age-related vision loss of ... million patients today to 55 million by the year 2050, ... vision even restored using molecular medicine. ... at the 10th annual meeting and International Conference on Recent ...
Cached Biology News:Carnegie Mellon researchers identify 'Facebook neurons' 2Carnegie Mellon researchers identify 'Facebook neurons' 3Researchers create 'scoring system' for PTEN mutation testing 2Molecular medicine could avert predicted catastrophic vision loss in the aged 2Molecular medicine could avert predicted catastrophic vision loss in the aged 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... strains are high-performance BL21 ... protein yield in T7 ... 1). Because the T7 ... more rapidly than E. ...
Biology Products: